Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Shionogi & Co., Ltd. Unsponsored ADR (SGIOY : OTC)
 
 • Company Description   
Shionogi & Co., Ltd. engages in the research, development, manufacture and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. Shionogi & Co., Ltd. is based in Osaka, Japan.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.75 Daily Weekly Monthly
20 Day Moving Average: 104,048 shares
Shares Outstanding: 1,701.38 (millions)
Market Capitalization: $14,887.07 (millions)
Beta: 0.20
52 Week High: $9.23
52 Week Low: $6.71
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.10% -0.06%
12 Week -1.80% -3.56%
Year To Date 25.72% 8.48%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1-8 DOSHOMACHI 3-CHOME
-
OSAKA,M0 541-0045
JPN
ph: 816-620-2216
fax: -
None http://www.shionogi.com
 
 • General Corporate Information   
Officers
Isao Teshirogi - President and CEO
Keiichi Ando - Chairperson
John Keller - Senior Executive Officer; Senior Vice President
Hiroshi Ozaki - Director
Takaoki Fujiwara - Director

Peer Information
Shionogi & Co., Ltd. Unsponsored ADR (GSAC)
Shionogi & Co., Ltd. Unsponsored ADR (CASI)
Shionogi & Co., Ltd. Unsponsored ADR (ALCD.)
Shionogi & Co., Ltd. Unsponsored ADR (OMNN)
Shionogi & Co., Ltd. Unsponsored ADR (CGPI.)
Shionogi & Co., Ltd. Unsponsored ADR (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 824667109
SIC: 8880
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 01/30/26
Share - Related Items
Shares Outstanding: 1,701.38
Most Recent Split Date: 10.00 (1.50:1)
Beta: 0.20
Market Capitalization: $14,887.07 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 1.45%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.13
Current Fiscal Year EPS Consensus Estimate: $0.70 Payout Ratio: 0.20
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.05
Estmated Long-Term EPS Growth Rate: 6.05% Last Dividend Paid: 09/26/2025 - $0.06
Next EPS Report Date: 01/30/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 12.50
Trailing 12 Months: 13.67
PEG Ratio: 2.07
Price Ratios
Price/Book: 1.50
Price/Cash Flow: 11.84
Price / Sales: 5.34
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 12.50%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 11.13%
ROE
09/30/25 - 11.90
06/30/25 - -
03/31/25 - -
ROA
09/30/25 - 10.63
06/30/25 - -
03/31/25 - -
Current Ratio
09/30/25 - 6.44
06/30/25 - 6.63
03/31/25 - 6.63
Quick Ratio
09/30/25 - 5.74
06/30/25 - 6.02
03/31/25 - 6.13
Operating Margin
09/30/25 - 39.53
06/30/25 - -
03/31/25 - -
Net Margin
09/30/25 - 39.53
06/30/25 - -
03/31/25 - -
Pre-Tax Margin
09/30/25 - -
06/30/25 - -
03/31/25 - 45.81
Book Value
09/30/25 - 5.84
06/30/25 - 5.35
03/31/25 - 5.29
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - 0.97
Debt-to-Equity
09/30/25 - 0.01
06/30/25 - 0.01
03/31/25 - 0.01
Debt-to-Capital
09/30/25 - 1.25
06/30/25 - 1.30
03/31/25 - 1.33
 

Powered by Zacks Investment Research ©